| Literature DB >> 35743586 |
Manuel Méndez-Bailon1, Noel Lorenzo-Villalba2, Jorge Rubio-Garcia3, María Carmen Moreno-García4, Guillermo Ropero-Luis5, Eduardo Martínez-Litago6, Raúl Quirós-López7, Sara Carrascosa-García8, Alvaro González-Franco9, Emmanuel Andrès2, Jesús Casado-Cerrada10, Manuel Montero-Pérez-Barquero11.
Abstract
BACKGROUND: Patients with heart failure encompass a heterogeneous group, but they are mostly elderly patients with a large burden of comorbid conditions.Entities:
Keywords: caregivers; heart failure; hospital readmission; mortality
Year: 2022 PMID: 35743586 PMCID: PMC9225050 DOI: 10.3390/jcm11123516
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.964
Baseline characteristics and outcomes of patients with HF according to caregiver.
| Variable | All | Partner | Children | Professional Caregiver | No Caregiver | |
|---|---|---|---|---|---|---|
| Age, | 81.06 (8.7) | 77.28 (9.05) | 83.63 (7.02) | 83.53 (8.2) | 76.6 * (10.7) | <0.001 |
| Sex: male, | 1022 (47.6) | 483 (68.7) * | 375 (34.2) | 76 (38.2) | 88 (59.5) | <0.001 |
| Sex: female, | 1125 (52.4) | 220 (31.3) | 722 (65.8) * | 123 (61.8) | 60 (40.5) | <0.001 |
| Comorbidities | ||||||
| Hypertension, | 1889 (88) | 604 (85.9) | 989 (90.2) | 176 (88.4) | 120 (81.1) * | <0.001 |
| T2DM, | 993 (46.3) | 367 (52.2) | 467 (42.6) | 82 (41.2) * | 77 (52) | <0.001 |
| COPD, | 448 (20.9) | 182 (25.9) * | 203 (18.5) | 34 (17.1) | 29 (19.6) | 0.001 |
| Atrial fibrillation, | 1172 (54.6) | 361 (51.4) | 629 (57.3) | 119 (59.8) | 63 (42.6) * | <0.001 |
| Ischemic heart disease, | 481 (22.4) | 190 (27) | 213 (19) | 167 (16) | 102 (31) * | <0.001 |
| Pfeiffer index, | 1.5 (1.9) | 1.08 (1.6) | 1.31 (1.7) | 2.02 (2.3) | 0.5 * (1.09) | <0.001 |
| Barthel index, median (SD) | 81.2 (24.09) | 89.2 (18.02) | 75.3 (25.9) | 73.8 (26.6) | 95.9 * (9.7) | <0.001 |
| Charlson score, | 3.05 (2.5) | 3.2 (2.6) | 3.02 (2.4) | 2.9 (2.4) | 2.6 * (3.2) | 0.035 |
| LVEF, median (SD) | 51.8 (15.7) | 50.3 (15.4) | 53.3 (15.7) | 54.5 (15.3) | 44.7 * (15.3) | <0.001 |
| Laboratory, | ||||||
| Hemoglobin, | 12.09 (2.04) | 12.3 (2.09) | 11.9 (1.9) | 11.8 * (1.9) | 12.5 (2.2) | <0.001 |
| Creatinine | 1.3 (2.6) | 1.2 (0.5) | 1.4 (3.6) | 1.2 (0.7) | 1.2 (0.5) | 0.692 |
| proBNP (pg/mL), median | 6654.6 | 5697.2 | 7108.06 | 7296.9 | 7555.1 | 0.058 |
| Non-pharmacological treatment | 19(0.88) | |||||
| Fluid restriction, | 1365 (70.5) | 417 (66.3) | 741 (73.7) | 124 (68.5) | 83 (65.9) | 0.008 |
| Weight monitoring, | 1555 (80) | 497 (79.1) | 803 (41.3) | 153 (84.1) | 102 (81) | 0.510 |
| Low-sodium diet, | 1814 (93) | 583 (92.4) | 949 (93.9) | 172 (94.5) | 110 (88) | 0.072 |
| Pharmacological treatment, | ||||||
| Beta blockers, | 1522 (70.9) | 516 (73.4) | 753 (68.6) | 127 (63.8) | 126 (85.1) * | <0.001 |
| ACE inhibitors/ARA-2, | 1266 (59) | 404 (57.5) | 654 (59.6%) | 131 (65.8) * | 77 (52) | 0.054 |
| Sacubitril valsartan, | 138 (6.4) | 42 (6) | 55 (5) | 6 (3) | 35 (25.4) * | <0.001 |
| Anti-aldosterone agents | 486 (22.6) | 180 (37) * | 233 (21.2) | 38 (19.1) | 35 (23.6) | 0.099 |
| Endpoints | ||||||
| Mortality at 30 days, | 546 (27.9) | 155 (29.2) | 299 (35.3) | 67 (35.3) | 25 (22.9) * | 0.011 |
| 30-day readmission, | 383 (19.7) | 109 (17.3) * | 201 (19.7) | 49 (26.1) | 24 (22.4) | 0.053 |
| Mortality at 120 days, | 630 (32.1) | 177 (27.8) * | 341 (33.3) | 76 (40) | 336 (33) | 0.010 |
| 120-day readmission, | 691 (35.5) | 207 (32.8) * | 355 (34.8) | 87 (46.3) | 42 (39.3) | 0.006 |
| One-year readmission, | 1365 (70.1) | 430 (68.1) | 718 (70.4) | 142 (75.5) | 75 (70.1) | 0.279 |
| One-year mortality, | 1208 (61.6) | 380 (59.7) | 635 (62) | 121 (63.7) | 72 (66.1) | 0.524 |
Legend: * adjusted residuals are outside the ranges +2 −2. T2DM: type 2 diabetes mellitus; COPD: chronic obstructive pulmonary disease; LVEF: left ventricular ejection fraction; ACE inhibitors: angiotensin-converting enzyme inhibitors; ARA-2: angiotensin II receptor antagonists.
Figure 1Survival analysis for readmissions in patients with HF according to caregiver type at 120-day follow-up.
Figure 2Survival analysis for mortality in patients with HF according to caregiver type at 120-day follow-up.